共 39 条
[1]
Coleman R.E.(2008)Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference Clin Cancer Res 14 6387-95
[2]
Guise T.A.(2008)Risks and benefits of bisphosphonates Br J Cancer 98 1736-40
[3]
Lipton A.(2001)Bone metastases: approaches to management Sem Oncol 28 28-34
[4]
Coleman R.E.(2008)Receptor activator of nuclear factor κB ligand and osteoprotegerin regulation of bone remodeling in health and disease Endocr Rev 29 155-92
[5]
Janjan N.(2011)Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis Bone 48 96-9
[6]
Kearns A.E.(2009)Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL J Bone Miner Res 24 182-95
[7]
Khosla S.(2011)Denosumab: in the prevention of skeletal-related events in patients with bone metastases from solid tumours Drugs 71 1059-69
[8]
Kostenuik P.J.(2010)Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study J Clin Oncol 28 5132-9
[9]
Lipton A.(2011)Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study Lancet 377 813-22
[10]
Goessl C.(2011)Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma J Clin Oncol 29 1125-32